 Hyloris targets regulatory approval in Europe, with possible further extensions About 5 of hospitalized patients is diagnosed with hypophosphatemia, with part of them needing direct treatment during andor after their hospital stay1 Liège, Belgium January 20th 2023 7AM CET Hyloris Pharmaceuticals SA Euronext Brussels: HYL, a specialty biopharma company committed to addressing unmet medical... The post Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Defi... 